Tags

Type your tag names separated by a space and hit enter

Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma".
J Dtsch Dermatol Ges. 2013 Aug; 11 Suppl 6:1-116, 1-126.JD

Abstract

This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the staging of melanoma, the AJCC classification of 2009 is used. The definitive excision margins are 0.5 cm for in situ melanomas, 1 cm for melanomas with up to 2 mm tumor thickness and 2 cm for thicker melanomas, they are reached in a secondary excision. From 1 mm tumor thickness, sentinel lymph node biopsy is recommended. For stages II and III, adjuvant therapy with interferon-alpha should be considered after careful analysis of the benefits and possible risks. In the stage of locoregional metastasis surgical treatment with complete lymphadenectomy is the treatment of choice. In the presence of distant metastasis mutational screening should be performed for BRAF mutation, and eventually for CKIT and NRAS mutations. In the presence of mutations in case of inoperable metastases targeted therapies should be applied. Furthermore, in addition to standard chemotherapies, new immunotherapies such as the CTLA-4 antibody ipilimumab are available. Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years.

Authors+Show Affiliations

Department of Dermatology, University Hospital Tübingen, Germany.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng ger

PubMed ID

24028775

Citation

Pflugfelder, Annette, et al. "Malignant Melanoma S3-guideline "diagnosis, Therapy and Follow-up of Melanoma"." Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, vol. 11 Suppl 6, 2013, pp. 1-116, 1-126.
Pflugfelder A, Kochs C, Blum A, et al. Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". J Dtsch Dermatol Ges. 2013;11 Suppl 6:1-116, 1-126.
Pflugfelder, A., Kochs, C., Blum, A., Capellaro, M., Czeschik, C., Dettenborn, T., Dill, D., Dippel, E., Eigentler, T., Feyer, P., Follmann, M., Frerich, B., Ganten, M. K., Gärtner, J., Gutzmer, R., Hassel, J., Hauschild, A., Hohenberger, P., Hübner, J., ... Schadendorf, D. (2013). Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 11 Suppl 6, 1-116, 1-126. https://doi.org/10.1111/ddg.12113_suppl
Pflugfelder A, et al. Malignant Melanoma S3-guideline "diagnosis, Therapy and Follow-up of Melanoma". J Dtsch Dermatol Ges. 2013;11 Suppl 6:1-116, 1-126. PubMed PMID: 24028775.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Malignant melanoma S3-guideline "diagnosis, therapy and follow-up of melanoma". AU - Pflugfelder,Annette, AU - Kochs,Corinna, AU - Blum,Andreas, AU - Capellaro,Marcus, AU - Czeschik,Christina, AU - Dettenborn,Therese, AU - Dill,Dorothee, AU - Dippel,Edgar, AU - Eigentler,Thomas, AU - Feyer,Petra, AU - Follmann,Markus, AU - Frerich,Bernhard, AU - Ganten,Maria-Katharina, AU - Gärtner,Jan, AU - Gutzmer,Ralf, AU - Hassel,Jessica, AU - Hauschild,Axel, AU - Hohenberger,Peter, AU - Hübner,Jutta, AU - Kaatz,Martin, AU - Kleeberg,Ulrich R, AU - Kölbl,Oliver, AU - Kortmann,Rolf-Dieter, AU - Krause-Bergmann,Albrecht, AU - Kurschat,Peter, AU - Leiter,Ulrike, AU - Link,Hartmut, AU - Loquai,Carmen, AU - Löser,Christoph, AU - Mackensen,Andreas, AU - Meier,Friedegund, AU - Mohr,Peter, AU - Möhrle,Matthias, AU - Nashan,Dorothee, AU - Reske,Sven, AU - Rose,Christian, AU - Sander,Christian, AU - Satzger,Imke, AU - Schiller,Meinhard, AU - Schlemmer,Heinz-Peter, AU - Strittmatter,Gerhard, AU - Sunderkötter,Cord, AU - Swoboda,Lothar, AU - Trefzer,Uwe, AU - Voltz,Raymond, AU - Vordermark,Dirk, AU - Weichenthal,Michael, AU - Werner,Andreas, AU - Wesselmann,Simone, AU - Weyergraf,Ansgar J, AU - Wick,Wolfgang, AU - Garbe,Claus, AU - Schadendorf,Dirk, AU - ,, AU - ,, PY - 2013/9/14/entrez PY - 2013/9/18/pubmed PY - 2014/4/12/medline SP - 1-116, 1-126 JF - Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG JO - J Dtsch Dermatol Ges VL - 11 Suppl 6 N2 - This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the staging of melanoma, the AJCC classification of 2009 is used. The definitive excision margins are 0.5 cm for in situ melanomas, 1 cm for melanomas with up to 2 mm tumor thickness and 2 cm for thicker melanomas, they are reached in a secondary excision. From 1 mm tumor thickness, sentinel lymph node biopsy is recommended. For stages II and III, adjuvant therapy with interferon-alpha should be considered after careful analysis of the benefits and possible risks. In the stage of locoregional metastasis surgical treatment with complete lymphadenectomy is the treatment of choice. In the presence of distant metastasis mutational screening should be performed for BRAF mutation, and eventually for CKIT and NRAS mutations. In the presence of mutations in case of inoperable metastases targeted therapies should be applied. Furthermore, in addition to standard chemotherapies, new immunotherapies such as the CTLA-4 antibody ipilimumab are available. Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years. SN - 1610-0387 UR - https://www.unboundmedicine.com/medline/citation/24028775/Malignant_melanoma_S3_guideline_"diagnosis_therapy_and_follow_up_of_melanoma"_ L2 - https://doi.org/10.1111/ddg.12113_suppl DB - PRIME DP - Unbound Medicine ER -